Jade Biosciences公司宣布,其在研的新型抗APRIL单克隆抗体药物Jade101已完成1期健康志愿者临床试验的首批受试者给药。该药物被认为具有潜在的同类最佳特性,正在接受IgA肾病治疗适应症的评估。
Jade Biosciences公司宣布,其在研的新型抗APRIL单克隆抗体药物Jade101已完成1期健康志愿者临床试验的首批受试者给药。该药物被认为具有潜在的同类最佳特性,正在接受IgA肾病治疗适应症的评估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.